关键信息
-
基因名
BCL9
- 应用
-
别名
BCL9；DLNB11；B-cell CLL/lymphoma 9-like Protein
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O00512
-
表达区间
174-396aa
-
氨基酸序列
AKVVYVFSTEMANKAAEAVLKGQVETIVSFHIQNISNNKTERSTAPLNTQISALRNDPKPLPQQPPAPANQDQNSSQNTRLQPTPPIPAPAPKPAAPPRPLDRESPGVENKLIPSVGSPASSTPLPPDGTGPNSTPNNRAVTPVSQGSNSSSADPKAPPPPPVSSGEPPTLGENPDGLSQEQLEHRERSLQTLRDIQRMLFPDEKEFTGAQSGGPQQNPGVLD
-
分子量
26.7 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
BCL9 is a key regulatory protein involved in the Wnt signaling pathway, which plays a crucial role in various biological processes, including cell proliferation, differentiation, and tumorigenesis. It acts as a co-activator for β-catenin, enhancing the transcription of Wnt target genes that are implicated in cancer progression and metastasis. Given its significant role in promoting oncogenic processes, BCL9 has emerged as a potential therapeutic target for cancer treatment. Recent studies have focused on the characterization and production of recombinant BCL9 proteins to better understand its structural and functional properties. This includes investigating its interaction with β-catenin and other molecular partners within the Wnt signaling cascade. By producing and analyzing recombinant BCL9, researchers aim to elucidate its mechanisms of action, potential post-translational modifications, and to assess its role in various cancers. Such investigations not only aim to advance our understanding of BCL9's involvement in tumors but also pave the way for developing targeted therapies that disrupt its function or its interactions with other critical components of the signaling pathway. The ongoing research highlights the importance of recombinant proteins in drug discovery and the potential for innovative treatment strategies in cancer therapy.
